Tom Steyer's Farallon Capital Doubles Down on Liquidia as Biopharma Giant Targets $1bn Valuation

Billionaire investor Tom Steyer has significantly increased his exposure to Liquidia Corporation through his fund, Farallon Capital, according to fourth quarter 2025 regulatory filings. The investment arm now holds 8.6 million shares of the biopharmaceutical firm, a substantial rise from the 2 million shares recorded in the first quarter of 2024. This renewed confidence from the elite investor coincides with a period of robust commercial performance for the company, which specialises in treating rare cardiopulmonary diseases.

The financial results accompanying the stake increase highlight a sharp acceleration in revenue generation. Liquidia reported product sales of $90.1 million for the quarter, representing a 74 per cent rise compared to the previous three months. This surge is primarily attributed to the market uptake of YUTREPIA, the company's dry-powder treprostinil treatment for pulmonary hypertension. Since the product achieved full commercial launch in June 2025, Liquidia has successfully captured a 17 per cent share of the inhaled treprostinil market.

CEO Roger Jeffs has outlined a clear strategic roadmap aimed at transforming the organisation into a billion-dollar franchise by 2027. This ambitious target relies heavily on the continued rapid adoption of YUTREPIA and the company's ability to expand its commercial reach. To support this growth, Liquidia is actively expanding its sales force to engage with more than 860 active prescribers, aiming to maximise the commercial potential of its key asset.

Despite the positive momentum, the company operates within a competitive landscape that includes ongoing litigation with its main rival, United Therapeutics. Nevertheless, the filing data suggests that institutional interest is driven by the transition of Liquidia from a clinical-stage entity to a profitable commercial powerhouse. The specific trajectory of the Farallon Capital stake, which saw the fund liquidate its earlier position in 2020 before re-entering in 2024, underscores a long-term belief in the firm's disruptive potential within its niche.

While the focus remains on the biopharmaceutical sector, the broader market context includes varied investment themes ranging from artificial intelligence to defensive equities. However, the specific fundamentals of Liquidia Corporation, particularly the sequential revenue growth and the backing of high-profile capital, present a distinct narrative for investors tracking the healthcare sector. The company's ability to navigate its competitive environment while executing its growth plan will be critical in realising the valuation targets set by its leadership.